Tiny Health announced a $33 million Series B led by B Capital, bringing its total funding to $46 million.
Existing and new investors participated in the round and the company announced a $5 million Microbiome Research Program to accelerate translational microbiome work.
The company plans to use the capital to advance clinical research and interventional studies, expand healthcare practitioner education, scale its Powered by Tiny B2B platform, and accelerate TinyAI, an AI trained on the company’s proprietary dataset of nearly 200,000 microbiome profiles.
Tiny Health claims it has published an interventional randomized controlled trial in 2025 showing a targeted microbiome intervention reduced infants’ odds of developing eczema by 83% and claims a second randomized trial is underway.
Founded in 2020 and launched in 2022, the company claims its platform uses shotgun metagenomic sequencing and serves nearly 200,000 customers and more than 6,000 healthcare practitioners.
